

Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

**NT Health Primary Health Remote Services SSTP
Revocation and Approval**

I, Christine Maree Connors, Chief Health Officer:

- (a) under section 254(5) of the *Medicines, Poisons and Therapeutic Goods Act 2012*, (***the Act***), revoke the instrument titled “NT Health Primary Health Remote Services SSTP Revocation and Approval” dated 17 May 2023 and
- (b) under section 254(1) of the Act, approve each Scheduled substance treatment protocol specified in Schedule A;
- (c) under section 254(3) of the Act, state that each Schedule substance treatment protocol specified in Schedule A remains in effect for a period of 2 years on and from the date of this instrument.

Dated

9 October 2023 @ 4.13pm

Chief Health Officer

Schedule A

Title	Publication Date	Author
Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual PPHC Remote SSTP	02/10/2023	Population and Primary Health Care, Northern Territory Government, Department of Health
Women's Business Manual PPHC Remote SSTP	02/10/2023	Population and Primary Health Care, Northern Territory Government, Department of Health
Men's Ceremonial Business PPHC Remote NT Health SSTP	02/10/2023	Population and Primary Health Care, Northern Territory Government, Department of Health
Mango Dermatitis PPHC Remote NT Health SSTP	02/10/2023	Population and Primary Health Care, Northern Territory Government, Department of Health
NT Immunisation Schedules PPHC NT Health SSTP	02/10/2023	Population and Primary Health Care, Northern Territory Government, Department of Health
Vaccination Schedule when Administering Workplace Staff Immunisation Program Vaccines to Adults in the Northern Territory (NT) Scheduled Substance Treatment Protocol (SSTP)	02/10/2023	Population and Primary Health Care, Northern Territory Government, Department of Health

Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual PPHC Remote SSTP

Areas Applicable	Services delivered at or through NT Health Primary Health Care Remote clinics		
Health Professionals authorised by this SSTP	Nurses Midwives Aboriginal and Torres Strait Islander Health Practitioners		
Scheduled Substance(s)	Adrenaline (Epinephrine)	Famciclovir	Praziquantel
	Albendazole	Fluoride Varnish	Prednisolone
	Amiodarone	Hydrocortisone	Probenecid
	Amoxicillin (Amoxycillin)	Ibuprofen	Procaine Benzylpenicillin (Procaine Penicillin)
	Clavulanic Acid	Ipratropium	Prochlorperazine
	Azithromycin	Iron	Salbutamol
	Benzathine Benzylpenicillin	Ivermectin	Terbinafine
	Benzatropine	Lidocaine (Lignocaine)	Tetracaine (Amethocaine)
	Betamethasone Valerate	Metoclopramide	Triamcinolone
	Box Jellyfish Antivenom (Antisera)	Metronidazole	Neomycin
	Cefalexin (Cephalexin)	Midazolam	Nystatin
	Ceftriaxone	Morphine	Trimethoprim
	Ciprofloxacin	Naloxone	Sulfamethoxazole
	Clindamycin	Omeprazole	Tuberculin PPD (Mantoux)
	Dexamethasone	Ondansetron	Valaciclovir
	Framycetin	Oxybuprocaine	Vaccine – Hepatitis A
	Gramicidin	Paracetamol when in combination with Codeine	Vaccine – Hepatitis B
	Doxycycline	Phenoxymethylpenicillin (Penicillin V)	
Indication	Individual scheduled substances are to be used according to the indication for which they are being administered as outlined in the Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual, 2022; 8th edition		
Contraindications and/or Exclusions*	<ul style="list-style-type: none"> Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol Any contraindications or exclusions as outlined in the individual scheduled substance product information 		

	<ul style="list-style-type: none"> Any contraindication or exclusions as outlined in the Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual, 2022; 8th edition
Dose and Route*	As per the individual scheduled substance and indication as outlined in the Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual, 2022; 8th edition
Administration	<p>As per the individual scheduled substance and indication as outlined in the Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual, 2022; 8th edition</p> <p>Medicines must not be administered by the intravenous route without the direction of a medical practitioner, except where the medical condition of the person requires the intravenous administration of the medicine without delay.</p>
Dose Frequency*	As per the individual scheduled substance and indication as outlined in the Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual, 2022; 8th edition
Drug Interactions*	As outlined in the individual scheduled substance product information
Monitoring requirements*	As per the individual scheduled substance and indication as outlined in the Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual, 2022; 8th edition
Health Professional Accreditation Requirements	<p>Nurses and Midwives</p> <ul style="list-style-type: none"> Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients Have completed all essential training as mandated for PPHC staff – see: <ul style="list-style-type: none"> Essential Training for Nursing and Midwifery Employees TEHS Guidelines.docx Essential Training PPHC CAHS Guideline.DOCX <p>Aboriginal & Torres Strait Islander Health Practitioners (ATSIHPs) must</p> <ul style="list-style-type: none"> Be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients Have completed all essential training as mandated for PPHC staff – see: <ul style="list-style-type: none"> Essential Training for Aboriginal and Torres Strait Islander Health Practitioners TEHS Guidelines.docx Essential Training PPHC CAHS Guideline.DOCX <p>All health professionals following this protocol must maintain continuing professional development related to skills and competencies required for delivery of medicines.</p>

Documentation <i>(including necessary information to the patient)</i>	Patients who receive scheduled substances in accordance with this SSTP must have this documented in the medication section of the patient's record within Primary Care Information System (PCIS)		
Related Documents	<ul style="list-style-type: none">• Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual, 2022; 8th edition• Approved Scheduled Substance Treatment Protocols (SSTP) and Medicines List PHC Remote.docx• Section 250 NT Medicines Poisons and Therapeutic Goods Act PPHC NT Health Guideline.docx• Standard Drug List PPHC Remote NT Health Master Document.xlsx		
Chief Health Officer	Signature	Name	Date
	EDOC2023/303299	Adj Pro Christine Connors	09/10/2023 @ 4.13pm
Period of effect	This SSTP is in effect until 09/10/2025		
References: * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration			

Mango Dermatitis PPHC Remote NT Health SSTP

Areas Applicable	Services delivered at or through NT Health Primary Health Care Remote clinics
Health Professionals authorised by this SSTP	Nurses Midwives Aboriginal and Torres Strait Islander Health Practitioners
Scheduled Substance(s)	<ul style="list-style-type: none"> Mometasone furoate Prednisolone
Indication	For use during the management of clinical conditions arising from men's business as outlined in the <i>Mango Dermatitis PPHC Remote Procedure</i>
Contraindications and/or Exclusions*	<ul style="list-style-type: none"> Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol Any contraindications or exclusions as outlined in the individual scheduled substance product information Any contraindications or exclusions as outlined in the individual scheduled substance Mango Dermatitis PPHC Remote Procedure
Dose and Route*	<p>Mometasone furoate 0.1% ointment</p> <ul style="list-style-type: none"> Apply liberally to affected areas morning and night for five (5) to seven (7) days <p>Prednisolone 25mg tablets</p> <ul style="list-style-type: none"> Take TWO (2) tablets daily in the morning (with food) for three (3) days
Administration	<p>As above.</p> <p>Medicines must not be administered by the intravenous route without the direction of a medical practitioner, except where the medical condition of the person requires the intravenous administration of the medicine without delay.</p>
Dose Frequency*	As above
Drug Interactions*	As outlined in the individual scheduled substance product information
Monitoring requirements*	<p>Refer to <i>Mango Dermatitis PPHC Remote Procedure</i>.</p> <p>All clients requiring treatment with oral prednisolone must return for review within three (3) days.</p> <ul style="list-style-type: none"> If showing no improvement after three (3) days, then medical consult If reaction is improving, change treatment to topical corticosteroids (Hydrocortisone 1% cream) – apply to affected areas twice daily for 5 days For pain management, refer to the CARPA Standard Treatment Manual, 8th edition Pain Management protocol

Health Professional Accreditation Requirements	<p>Nurses and Midwives</p> <ul style="list-style-type: none">• Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients• Have completed all essential training as mandated for PPHC staff – see:<ul style="list-style-type: none">○ Essential Training for Nursing and Midwifery Employees TEHS Guidelines.docx○ Essential Training PPHC CAHS Guideline.DOCX <p>Aboriginal & Torres Strait Islander Health Practitioners (ATSIHPs) must</p> <ul style="list-style-type: none">• Be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients• Have completed all essential training as mandated for PPHC staff – see:<ul style="list-style-type: none">○ Essential Training for Nursing and Midwifery Employees TEHS Guidelines.docx○ Essential Training PPHC CAHS Guideline.DOCX <p>All health professionals following this protocol must maintain continuing professional development related to skills and competencies required for delivery of medicines.</p>		
Documentation <i>(including necessary information to the patient)</i>	Patients who receive scheduled substances in accordance with this SSTP must have this documented in the medication section of the patient's record within Primary Care Information System (PCIS)		
Related Documents	<ul style="list-style-type: none">• Mango Dermatitis PPHC Remote Procedure• Central Australian Rural Practitioners Association (CARPA) Standard Treatment Manual, 2022; 8th edition• Approved Scheduled Substance Treatment Protocols (SSTP) and Medicines List PHC Remote.docx• Section 250 NT Medicines Poisons and Therapeutic Goods Act PPHC NT Health Guideline.docx• Standard Drug List PPHC Remote NT Health Master Document.xlsx		
Chief Health Officer	Signature	Name	Date
	EDOC2023/303299	Adj Prof Christine Connors	09/10/2023 @ 4.13pm
Period of effect	This SSTP is in effect until 09/10/2025		
References: * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product			

info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration

Men's Ceremonial Business PPHC Remote NT Health SSTP

Areas Applicable	Services delivered at or through NT Health Primary Health Care Remote clinics
Health Professionals authorised by this SSTP	Nurses Midwives Aboriginal and Torres Strait Islander Health Practitioners
Scheduled Substance(s)	<ul style="list-style-type: none"> Clindamycin Trimethoprim/Sulfamethoxazole combination Amoxicillin/Clavulanic acid combination Ceftriaxone Paracetamol/Codeine phosphate combination
Indication	For use during the management of clinical conditions arising from men's business as outlined in the Men's Ceremonial Business PPHC Remote Procedure
Contraindications and/or Exclusions*	<ul style="list-style-type: none"> Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol Any contraindications or exclusions as outlined in the individual scheduled substance product information Any contraindications or exclusions as outlined in the individual scheduled substance Men's Ceremonial Business PPHC Remote Procedure
Dose and Route*	<ul style="list-style-type: none"> Paracetamol 500mg/Codeine phosphate 30mg, 2 tablets oral once only <p>During Ceremony:</p> <ul style="list-style-type: none"> Oral Clindamycin 450mg BD 2 doses; OR Oral Trimethoprim/Sulfamethoxazole 160+800mg BD 2 dose; OR Amoxicillin/Clavulanic acid 875+125mg BD 2 doses; <p>After Ceremony (Presentation to health centre):</p> <ul style="list-style-type: none"> IV/IM Ceftriaxone 1g STAT; AND Oral Trimethoprim/Sulfamethoxazole 160+800mg BD 5 days; OR Oral Clindamycin 450mg TDS for 5 days
Administration	<p>As above.</p> <p>Medicines must not be administered by the intravenous route without the direction of a medical practitioner, except where the medical condition of the person requires the intravenous administration of the medicine without delay.</p>

Dose Frequency*	As above		
Drug Interactions*	As outlined in the individual scheduled substance product information		
Monitoring requirements*	As per the Men's Ceremonial Business PPHC Remote Procedure		
Health Professional Accreditation Requirements	<p>Nurses and Midwives</p> <ul style="list-style-type: none"> • Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients • Have completed all essential training as mandated for PPHC staff – see: <ul style="list-style-type: none"> ○ Essential Training for Nursing and Midwifery Employees TEHS Guidelines.docx ○ Essential Training PPHC CAHS Guideline.DOCX <p>Aboriginal & Torres Strait Islander Health Practitioners (ATSIHPs) must</p> <ul style="list-style-type: none"> • Be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients • Have completed all essential training as mandated for PPHC staff - see: <ul style="list-style-type: none"> ○ Essential Training for Aboriginal and Torres Strait Islander Health Practitioners TEHS Guidelines.docx ○ Essential Training PPHC CAHS Guideline.DOCX <p>All health professionals following this protocol must maintain continuing professional development related to skills and competencies required for delivery of medicines.</p>		
Documentation <i>(including necessary information to the patient)</i>	Patients who receive scheduled substances in accordance with this SSTP must have this documented in the medication section of the patient's record within Primary Care Information System (PCIS)		
Related Documents	<ul style="list-style-type: none"> • Men's Ceremonial Business PPHC Remote Procedure • CARPA Standard Treatment Manual RPHCM (remotephcmmanuals.com.au) • Approved Scheduled Substance Treatment Protocols (SSTP) and Medicines List PHC Remote.docx • Section 250 NT Medicines Poisons and Therapeutic Goods Act PPHC NT Health Guideline.docx • Standard Drug List PPHC Remote NT Health Master Document.xlsx 		
Chief Health Officer	Signature	Name	Date
	EDOC2023/303299	Adj Prof Christine Connors	09/10/2023 @ 4.13pm

Period of effect	This SSTP is in effect until 09/10/2025
References: * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration	

NT Immunisation Schedules PPHC NT Health SSTP

Areas Applicable	Services delivered at or through NT Health Primary Health Care		
Health Professionals authorised by this SSTP	Nurses Midwives Aboriginal and Torres Strait Islander Health Practitioners		
Scheduled Substance(s)	The following vaccines for human therapeutic use as single vaccines or in combination:		
	Diphtheria	Haemophilus Influenza B	Tetanus
	Pertussis	Poliomyelitis	Herpes Zoster
	Hepatitis A	Hepatitis B	Measles
	Human Papillomavirus	Influenza	Meningococcal
	Mumps	Rubella	Varicella
	Pneumococcal	Rotavirus	
	COVID-19 - Follow current COVID-19 Vaccine Scheduled Substance Treatment Protocols		
Indication	Individual scheduled substances are to be used according to the indication for which they are being administered as outlined in the: <ul style="list-style-type: none">NT Immunisation Schedule Children;NT Immunisation Schedule Adult and Special risk Groups;NT Immunisation Schedule Pneumococcal Vaccination		
Contraindications and/or Exclusions*	<ul style="list-style-type: none">Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocolAny contraindications or exclusions as outlined in the individual scheduled substance product informationAny contraindication or exclusions as outlined in the NT Immunisation Schedules and the Australian Immunisation Handbook		
Dose and Route*	As per the individual scheduled substance and indication as outlined in the NT Immunisation Schedules and the Australian Immunisation Handbook		
Administration	As per the individual scheduled substance and indication as outlined in the NT Immunisation Schedules and the Australian Immunisation Handbook		
Dose Frequency*	As per the individual scheduled substance and indication as outlined in the NT Immunisation Schedules and the Australian Immunisation Handbook		

Drug Interactions*	As outlined in the individual scheduled substance product information
Monitoring requirements*	As per the individual scheduled substance and indication as outlined in the NT Immunisation Schedules and the Australian Immunisation Handbook
Health Professional Accreditation Requirements	<p>Nurses and Midwives must:</p> <ul style="list-style-type: none"> • Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients • Have completed all essential training as mandated for PPHC staff – see: <ul style="list-style-type: none"> ○ Essential Training for Nursing and Midwifery Employees TEHS Guidelines.docx ○ Essential Training PPHC CAHS Guideline.DOCX <p>Aboriginal & Torres Strait Islander Health Practitioners (ATSIHPs) must:</p> <ul style="list-style-type: none"> • Be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients • Have completed all essential training as mandated for PPHC staff - see: <ul style="list-style-type: none"> ○ Essential Training for Aboriginal and Torres Strait Islander Health Practitioners TEHS Guidelines.docx ○ Essential Training PPHC CAHS Guideline.DOCX <p>All health professionals following this protocol must:</p> <ul style="list-style-type: none"> • Maintain continuing professional development related to skills and competencies required for the delivery of medicines and vaccines including the use of multi-dose vials and management of anaphylaxis • Hold a current Cardiopulmonary Resuscitation (CPR) certificate <p>All health professionals administering vaccines from this protocol must have completed:</p> <ul style="list-style-type: none"> • A program of study for the administration of vaccines accredited by Health Education Services Australia (HESA) or; • A program of study specific for their profession approved by the Chief Health Officer for administration of vaccinations or; • completed the assessment of an immuniser program of study that meets the curriculum content requirements of the National Immunisation Education Framework for Health Professionals
Documentation (including necessary information to the patient)	Patients who receive scheduled substances in accordance with this SSTP must have this documented in the medication section of the patient's record within Primary Care Information System (PCIS)

	Entry into the Australian Immunisation Register (AIR) <ul style="list-style-type: none">Immunisation data including patient details, vaccine brand name, dose, site of administration and batch number should be entered or uploaded to AIR within 24 hours after administration or if not practical then the vaccination information must be entered within 10 business days.		
Related Documents	<ul style="list-style-type: none">NT Immunisation Schedule ChildrenNT Immunisation Schedule Adult and Special risk GroupsNT Immunisation Schedule Pneumococcal VaccinationCOVID-19 vaccine Protocols NT HealthAustralian Immunisation Handbook		
Chief Health Officer	Signature	Name	Date
	EDOC2023/303299	Adj Prof Christine Connors	09/10/2023 @ 4.13pm
Period of effect	This SSTP is in effect until 09/10/2025		
References: * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration			

Vaccination Schedule when Administering Workplace Staff Immunisation Program Vaccines to Adults in the Northern Territory (NT) PPHC Scheduled Substance Treatment Protocol (SSTP)

Areas Applicable	Services delivered at or through NT Health Primary Health Care
Health Professionals Authorised by this SSTP	Nurses Midwives Aboriginal and Torres Strait Islander Health Practitioners
Scheduled Substance(s)	<p>The following vaccines for human therapeutic use:</p> <ul style="list-style-type: none"> - Diphtheria, Tetanus, Pertussis (as single ingredients or combination) - Hepatitis A - Hepatitis B - Measles, Mumps, Rubella (combination) - Varicella - Influenza <p>Note: for COVID-19 - Follow current COVID-19 Vaccine Scheduled Substance Treatment Protocols</p>
Indication	When providing vaccinations for adults under a workplace staff immunisation program for vaccines that fall outside of the NT Vaccination Schedule and in accordance with the Australian Immunisation Handbook or relevant COVID19 Vaccine Scheduled Substance Treatment Protocols
Contraindications and/or Exclusions*	<p>For all vaccines:</p> <p>Anaphylaxis following any previous dose of the vaccine</p> <p>Anaphylaxis following any vaccine component</p> <p>Vaccine specific contraindications exist for some vaccines and are described in the relevant chapters in the Australian Immunisation Handbook.</p>
Dose and Route*	<p>Dose should be given as per the Australian Immunisation Handbook and Product Information.</p> <p>Preferred route is in the deltoid muscle of the upper arm. However alternate sites, such as vastus lateralis muscle of the thigh or ventrogluteal muscle of the hip, may also be used at clinician's discretion.</p>
Dose Frequency*	According to the Australian Immunisation Handbook

Vaccination Schedule when Administering Workplace Staff Immunisation Program Vaccines to Adults in the Northern Territory (NT) Scheduled Substance Treatment Protocol (SSTP)

Administration*	According to the Australian Immunisation Handbook and relevant Product Information for each vaccine
Drug Interactions*	<p>Refer to the Australian Immunisation Handbook for specific vaccines and their interactions with immunoglobulins.</p> <p>Refer to vaccine specific chapters in the Australian Immunisation Handbook for specific drug interactions with each vaccine.</p> <p>Clients receiving influenza vaccine who are taking warfarin, theophylline, phenytoin, phenobarbitone or carbamazepine should be advised to look out for signs of elevated levels of medication.</p>
Monitoring requirements*	<p>A pre-vaccination questionnaire should be undertaken prior to each vaccine encounter.</p> <p>All vaccine recipients should be observed for 15 minutes following vaccination for possible adverse events or anaphylaxis.</p>
Health Practitioner Education and Training Requirements	<p>Nurses and Midwives</p> <ul style="list-style-type: none"> • Hold registration with the Nursing and Midwifery Board of Australia with no conditions, notations or undertakings which may limit delivery of clinical services directly to patients • Have completed all essential training as mandated for PPHC staff – see: <ul style="list-style-type: none"> ○ Essential Training for Nursing and Midwifery Employees TEHS Guidelines.docx ○ Essential Training PPHC CAHS Guideline.DOCX <p>Aboriginal & Torres Strait Islander Health Practitioners (ATSIHPs)</p> <ul style="list-style-type: none"> • Be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients • Have completed all essential training as mandated for PPHC staff - see: <ul style="list-style-type: none"> ○ Essential Training for Aboriginal and Torres Strait Islander Health Practitioners TEHS Guidelines.docx ○ Essential Training PPHC CAHS Guideline.DOCX <p>All health professionals following this protocol must:</p> <ul style="list-style-type: none"> • Maintain continuing professional development related to skills and competencies required for the delivery of medicines and vaccines including the use of multi-dose vials and management of anaphylaxis • Hold a current Cardiopulmonary Resuscitation (CPR) certificate <p>All health professionals administering vaccines from this protocol must have completed:</p>

Vaccination Schedule when Administering Workplace Staff Immunisation Program Vaccines to Adults in the Northern Territory (NT) Scheduled Substance Treatment Protocol (SSTP)

	<ul style="list-style-type: none">• A program of study for the administration of vaccines accredited by Health Education Services Australia (HESA) or;• A program of study specific for their profession approved by the Chief Health Officer for administration of vaccinations or;• completed the assessment of an immuniser program of study that meets the curriculum content requirements of the National Immunisation Education Framework for Health Professionals.		
Documentation <i>(including necessary information to the patient)</i>	<p>Clients who receive any of the vaccines included on this SSTP must have the name, dose and batch number of the vaccine recorded in the medication section of the client's medical record. A copy should ideally be given to the client as a hand held record.</p> <p>Entry into the Australian Immunisation Register (AIR)</p> <ul style="list-style-type: none">• Immunisation data including patient details, vaccine brand name, dose, site of administration and batch number should be entered or uploaded to AIR within 24 hours after administration or if not practical then the vaccination information must be entered within 10 business days.		
Related Documents	<ul style="list-style-type: none">• COVID-19 vaccine Protocols NT Health• Australian Immunisation Handbook• Pre-employment Health Screening NT Health Policy		
Chief Health Officer	Signature	Name	Date
	EDOC2023/303299	Adj Prof Christine Connors	09/10/2023 @ 4.13pm
Date for Review	This SSTP is in effect until 09/10/2025		
References: * The drug information provided is to act as a guide only, for further information reference should be made to the full manufacturer's product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration			

Minymaku Kutju Tjukurpa Women's Business Manual PPHC Remote SSTP

Areas Applicable	Services delivered at or through NT Health Primary Health Care Remote clinics		
Health Professionals authorised by this SSTP	Nurses Midwives Aboriginal and Torres Strait Islander Health Practitioners		
Scheduled Substance(s)	Amoxicillin	Ceftriaxone	Oxytocin
	Azithromycin	Doxycycline	Paracetamol when in combination with Codeine
	Benzathine Benzylpenicillin	Metronidazole	Phenoxymethylpenicillin (Penicillin V)
	Cefalexin	Nitrofurantoin	Probenecid
Indication	Individual scheduled substances are to be used according to the indication for which they are being administered as outlined in the Minymaku Kutju Tjukurpa Women's Business Manual, 7th Edition, 2022		
Contraindications and/or Exclusions*	<ul style="list-style-type: none"> Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol Any contraindications or exclusions as outlined in the individual scheduled substance product information Any contraindication or exclusions as outlined in the Minymaku Kutju Tjukurpa Women's Business Manual, 7th Edition, 2022 		
Dose and Route*	As per the individual scheduled substance and indication as outlined in the Minymaku Kutju Tjukurpa Women's Business Manual, 7th Edition, 2022		
Administration	<p>As per the individual scheduled substance and indication as outlined in the Minymaku Kutju Tjukurpa Women's Business Manual, 7th Edition, 2022</p> <p>Medicines must not be administered by the intravenous route without the direction of a medical practitioner, except where the medical condition of the person requires the intravenous administration of the medicine without delay.</p>		
Dose Frequency*	As per the individual scheduled substance and indication as outlined in the Minymaku Kutju Tjukurpa Women's Business Manual, 7th Edition, 2022		
Drug Interactions*	As outlined in the individual scheduled substance product information		
Monitoring requirements*	As per the individual scheduled substance and indication as outlined in the Minymaku Kutju Tjukurpa Women's Business Manual, 7th Edition, 2022		

Health Professional Accreditation Requirements	Nurses and Midwives must: <ul style="list-style-type: none">• Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients• Have completed all essential training as mandated for PPHC staff – see:<ul style="list-style-type: none">○ Essential Training for Nursing and Midwifery Employees TEHS Guidelines.docx○ Essential Training PPHC CAHS Guideline.DOCX Aboriginal & Torres Strait Islander Health Practitioners (ATSIHPs) must: <ul style="list-style-type: none">• Be registered with the Aboriginal and Torres Strait Islander Health Practice Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients• Have completed all essential training as mandated for PPHC staff - see:<ul style="list-style-type: none">○ Essential Training for Aboriginal and Torres Strait Islander Health Practitioners TEHS Guidelines.docx○ Essential Training PPHC CAHS Guideline.DOCX All health professionals following this protocol must maintain continuing professional development related to skills and competencies required for delivery of medicines.		
Documentation <i>(including necessary information to the patient)</i>	Patients who receive scheduled substances in accordance with this SSTP must have this documented in the medication section of the patient’s record within Primary Care Information System (PCIS)		
Related Documents	<ul style="list-style-type: none">• Minymaku Kutju Tjukurpa Women’s Business Manual, 7th Edition, 2022• Approved Scheduled Substance Treatment Protocols (SSTP) and Medicines List PHC Remote.docx• Section 250 NT Medicines Poisons and Therapeutic Goods Act PPHC NT Health Guideline.docx• Standard Drug List PPHC Remote NT Health Master Document.xlsx		
Chief Health Officer	Signature EDOC2023/303299	Name Adj Prof Christine Connors	Date 09/10/2023 @ 4.13pm
Period of effect	This SSTP is in effect until 09/10/2025		
References: * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer’s product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration			